Drug Shortage Report for TEVA-BUDESONIDE
Report ID | 195815 |
Drug Identification Number | 02465949 |
Brand name | TEVA-BUDESONIDE |
Common or Proper name | TEVA-BUDESONIDE |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | BUDESONIDE |
Strength(s) | 0.125MG |
Dosage form(s) | SUSPENSION |
Route of administration | INHALATION INHALATION |
Packaging size | 2 |
ATC code | R03BA |
ATC description | OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-06-19 |
Estimated end date | 2023-07-20 |
Actual end date | 2023-07-05 |
Shortage status | Resolved |
Updated date | 2023-07-06 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2023-07-06 | English | Compare |
v4 | 2023-07-05 | French | Compare |
v3 | 2023-07-05 | English | Compare |
v2 | 2023-06-20 | French | Compare |
v1 | 2023-06-20 | English | Compare |
Showing 1 to 5 of 5